The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Read more: FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia